✦ LIBER ✦

Safety and efficacy (PASI 90 and global evaluation) of subcutaneous certolizumab pegol in patients with moderate to severe chronic plaque psoriasis: Results from a double-blind, placebo-controlled trial

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of subcutaneous cert

📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 53 KB

A randomized, double-blind, placebo-cont

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 55 KB

Efficacy and safety of topical WBI-1001

✍ R. Bissonnette; C. Bolduc; C. Maari; S. Nigen; J.M. Webster; L. Tang; M. Lyle 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 243 KB

A phase IV randomized, double-blind, pla

📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Adalimumab in Japanese patients with mod

✍ Akihiko ASAHINA; Hidemi NAKAGAWA; Takafumi ETOH; Mamitaro OHTSUKI; THE ADALIMUMA 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 490 KB

Patient-reported outcomes in moderate-to

✍ S. Tyring; J. Bagel; C. Lynde; P. Klekotka; E.H.Z. Thompson; S.R. Gandra; Y. Shi 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB